Results of a new study “support the therapeutic potential of cannabinoids in patients with OSA [obstructive sleep apnea]”.
For the study, published in the journal Sleep and epublished ahead of print by the National Institute of Health, “73 adults with moderate or severe OSA received either placebo (N=25), 2.5mg dronabinol (N=21) or 10mg dronabinol (N=27) daily, one hour before bedtime for up to 6 weeks.” Dronabinol, also called Marinol, is a synthetic THC meant to mimic the effects of natural, cannabis-based THC.
‘These findings support the therapeutic potential of cannabinoids in patients with OSA” states the study’s abstract. “In comparison to placebo, dronabinol was associated with lower AHI [Apnea–hypopnea index], improved subjective sleepiness and greater overall treatment satisfaction. Larger scale clinical trials will be necessary to clarify the best potential approach(es) to cannabinoid therapy in OSA.”
The full study can be found by clicking here.